As of 2025-06-22, the Intrinsic Value of Charles River Laboratories International Inc (CRL) is 184.22 USD. This CRL valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 147.45 USD, the upside of Charles River Laboratories International Inc is 24.90%.
The range of the Intrinsic Value is 113.85 - 379.61 USD
Based on its market price of 147.45 USD and our intrinsic valuation, Charles River Laboratories International Inc (CRL) is undervalued by 24.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 113.85 - 379.61 | 184.22 | 24.9% |
| DCF (Growth 10y) | 194.10 - 579.43 | 296.78 | 101.3% |
| DCF (EBITDA 5y) | 185.95 - 259.63 | 206.92 | 40.3% |
| DCF (EBITDA 10y) | 264.78 - 395.50 | 307.97 | 108.9% |
| Fair Value | -3.21 - -3.21 | -3.21 | -102.18% |
| P/E | (12.76) - 115.46 | 34.88 | -76.3% |
| EV/EBITDA | 136.39 - 222.02 | 166.93 | 13.2% |
| EPV | 100.18 - 158.82 | 129.50 | -12.2% |
| DDM - Stable | (5.13) - (16.18) | (10.65) | -107.2% |
| DDM - Multi | 91.62 - 232.07 | 132.26 | -10.3% |
| Market Cap (mil) | 7,242.74 |
| Beta | 0.39 |
| Outstanding shares (mil) | 49.12 |
| Enterprise Value (mil) | 9,527.61 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.17% |
| Cost of Debt | 4.78% |
| WACC | 7.92% |